Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects

The development of humanized monoclonal antibodies (MAbs) with Lutetium-177 ([ 177 Lu]Lu 3+ ) has brought a paradigm shift in the arena of targeted therapy of various cancers. [ 177 Lu]Lu-DOTA-Rituximab and [ 177 Lu]Lu-DOTA-Trastuzumab have gained prominence due to their improved therapeutic efficac...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular imaging and biology Vol. 26; no. 1; pp. 61 - 80
Main Authors:	Chakraborty, Avik, Mitra, Arpit, Sahu, Sudeep, Tawate, Megha, Lad, Sangita, Kamaldeep, Rakshit, Sutapa, Upadhye Bannore, Trupti, Gaikwad, Sujay, Dhotre, Geetanjali, Ray, Mukti Kanta, Damle, Archana, Basu, Sandip, Banerjee, Sharmila
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-02-2024 Springer Nature B.V
Subjects:	Ascorbic acid Breast cancer Breast carcinoma Conjugation Imaging Immunoconjugates Localization Lutetium Lutetium isotopes Lymphoma Medicine Medicine & Public Health Metastases Monoclonal antibodies Patients Radiochemistry Radiolabelling Radiology Research Article Rituximab Trastuzumab Clinical and pre-clinical study Radioimmunotherapy Rituximab Breast cancer Lu-177 Lymphoma Trastuzumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!